Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Published Date: 29 Oct 2026

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Read Full News

Latest News

ATTACK: Should Patients With CKD Start Aspirin for Primary Prevention? Hugh Gallagher, MD

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

RENEW-HD: Portable Hemodialysis Data, With Karin Gerritsen, MD, PhD

RENEW-HD: Portable Hemodialysis Data, With Karin Gerritsen, MD, PhD

Interpreting Kidney Donor Pregnancy Signals, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Chance, biology, and shared genetics may explain more small for gestational age births after living kidney donation.

Does CKD Require Restricting Potassium-Rich Foods? With Navdeep Tangri, MD Navdeep Tangri, MD

In a randomized crossover trial, a liberalized produce diet raised urinary potassium excretion without changing serum potassium.

Pentoxifylline in Diabetic Kidney Disease: What the Evidence Shows Rajiv Agarwal, MD, MS

Rajiv Agarwal, MD, MS, explains why decades of pentoxifylline data in DKD remain inconclusive and how the VA PTXRx trial aims to settle the question.

eGFR Underestimates CKD in Patients with Cancer, Study Finds

eGFR Underestimates CKD in Patients with Cancer, Study Finds

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Latest News

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

RENEW-HD: Portable Hemodialysis Data, With Karin Gerritsen, MD, PhD

Chance, biology, and shared genetics may explain more small for gestational age births after living kidney donation.

In a randomized crossover trial, a liberalized produce diet raised urinary potassium excretion without changing serum potassium.

Rajiv Agarwal, MD, MS, explains why decades of pentoxifylline data in DKD remain inconclusive and how the VA PTXRx trial aims to settle the question.

eGFR Underestimates CKD in Patients with Cancer, Study Finds

News All Time

Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna Norouzi, MD Sayna Norouzi, MD

Final ORIGIN 3 analysis shows a 76% lower risk of kidney disease progression vs placebo through 2 years.

Ochsner Health Expands Liver Transplant Access Through Multidisciplinary Care Ari Cohen, MD, MBA

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD Sayna Norouzi, MD

An AHA statement co-author says reproductive and family planning concerns belong in kidney care for women with glomerular disease.

Pregnancy After Living Kidney Donation, With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

Amit X. Garg, MD, PhD, discusses new JAMA data on preeclampsia risk after living kidney donation in a 3-part video interview.

Felzartamab and the Hidden Injury of Isolated MVI, With Yasir Qazi, MD Yasir Qazi, MD

TRANSPIRE investigator Yasir Qazi, MD, explains how isolated MVI can signal kidney transplant injury before creatinine rises.

I CAN: Ravulizumab Cuts Proteinuria 43% vs Placebo in IgA Nephropathy

I CAN: Ravulizumab Cuts Proteinuria 43% vs Placebo in IgA Nephropathy

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy Abigail Brooks, MA

Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.

IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy

IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy

RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy

RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

You Don't Need to Be a GN Specialist to Identify Glomerular Disease Earlier George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains the barriers in GN care that ASN's new compendium may address.

Uromodulin Drop Offers Clues to SGLT2 Kidney Protection, With Greco Malijan, MD Greco Malijan, MD

In EMPA-KIDNEY, empagliflozin cut urinary uromodulin 63% without signs of tubular injury, reshaping views on SGLT2 inhibitor mechanisms.

New ASN Compendium Tackles Fragmented GN Care, With Vasquez-Rios, MD George Vasquez-Rios, MD

A new ASN compendium curates scattered GN care guidance into one living resource, says nephrologist George Vasquez-Rios, MD

ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Recommended News For You

Cancer patients want financial screening early in care, study finds

Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.

Survival is extended by a new treatment option for metastatic colorectal cancer.

Insurance Claim Denials for Preventive Care More Common in At-Risk Patients

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

A new FDA boxed warning; suicides rocking college campuses; more people getting flu shots than COVID vaccines.

Breast cancer-related fatigue: The benefits of adapted physical activity

Recommended Articles For You

What Is A Normal Fibrinogen Level, And How Can It Affect Your Health 

Cancer Care Access Across Communities: Epidemiology, Clinical Insights, and Emerging Solutions 

Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons 

Preventing Bleeding Complications During Anticoagulant Transitions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A Lot Can Be Said About You by Including Yourself in Photos.

2.

A new blood test greatly increases the ability to detect cancer.

3.

Novel biomarker has potential for predicting and treating skin cancer metastasis

4.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

5.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

1.

Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy 

2.

Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice

3.

Contemporary Frameworks in Oncology Across Clinical Settings

4.

What is Mullerian and How Does it Affect Your Health

5.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Understanding Common Causes of Abnormal Blood Counts

2.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

3.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

4.

Understanding Cancer: Early Detection and Treatment

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot